Eli Lilly and Company, a leading pharmaceutical company, revealed groundbreaking results from a Phase 3 study of lebrikizumab, an investigational medicine designed for individuals with skin of color and moderate-to-severe atopic dermatitis, also known as eczema. The study showcased promising improvements in skin clearance and itch relief, offering hope for those who often face more severe symptoms and limited treatment options. Presented at the American Academy of Dermatology Annual Meeting, these results indicate the potential for lebrikizumab to become a primary biologic treatment post-topical therapies for a diverse group of patients.
Dr. Andrew Alexis, a renowned dermatologist and lead study investigator, emphasized the significance of addressing the needs of patients with skin of color affected by atopic dermatitis, a group historically underrepresented in clinical trials. The study included a diverse patient population, with 80% identifying as Black or African American, among others. Positive outcomes were observed, with a significant percentage experiencing substantial improvement in disease severity and skin appearance, along with relief from itching.
Notably, lebrikizumab’s safety profile remained favorable, with no serious adverse events reported. The study’s future presentations will provide additional insights into the treatment’s efficacy and safety. Dr. Mark Genovese, Lilly’s senior vice president of Immunology Development, underscored the importance of addressing inequities in dermatologic care and providing breakthrough solutions for underserved populations, including those with skin of color.
Lebrikizumab is a monoclonal antibody targeting IL-13, a key cytokine in atopic dermatitis, aiming to mitigate inflammatory processes in the skin. The Phase 3 program, including various global studies, is expected to yield more data on the treatment’s effectiveness, with upcoming results dedicated to patients previously treated with dupilumab. Lilly’s commitment to advancing health equity in dermatology involves engaging in impactful research, supporting healthcare providers, and empowering patient voices to drive meaningful solutions.
As Lilly continues its efforts to enhance patient care and promote diversity in clinical trials, the company remains dedicated to turning scientific discoveries into healing solutions that improve millions of lives worldwide. With a focus on addressing significant health challenges and ensuring accessibility to innovative treatments, Lilly stands at the forefront of biotechnological advancements. For more information on Lilly’s initiatives and developments, visit Lilly.com or follow the company on social media platforms for updates.
Photo: https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=original
SOURCE Eli Lilly and Company
Source link
